Replimune Group (7R8) Stock Price & Analysis
7R8 Stock Chart & Stats
- Day’s Range
- EUR 14.79 - EUR 15.82
- 52-Week Range
- EUR 1.43 - EUR 16.00
- Previous Close
- EUR 16.00
- Volume
- N/A
- Average Volume (3M)
- 45
- Market Cap
- EUR 1.49B
- Enterprise Value
- EUR 1.21B
- Total Cash (Recent Filing)
- EUR 307.83M
- Total Debt (Recent Filing)
- EUR 127.19M
- Price to Earnings (P/E)
- ―
- Beta
- 0.95
- Next Earnings
- Aug 12, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Validation And Commercial Entry
Accelerated FDA approval moves Replimune’s lead therapy from development toward commercialization in a difficult-to-treat melanoma setting. This creates an initial pathway to revenue, validates the clinical program, and may support broader adoption if confirmatory evidence sustains the approval.
Proprietary Immunotherapy Platform
Replimune’s ImmunoVirotherapy platform provides a focused technology base rather than a single isolated drug candidate. The ability to develop related oncolytic viruses across tumor types and combine them with checkpoint inhibitors could support pipeline expansion and longer-term innovation.
Improved Funding Flexibility
The substantial equity raise gives Replimune additional capital to advance its immuno-oncology portfolio, support commercialization, and fund ongoing clinical trials. Greater liquidity can extend operating capacity and reduce the immediate pressure to secure financing while programs mature.
Bears Say
No Commercial Revenue Yet
Replimune remains pre-commercial in the financial data despite receiving accelerated approval, so its operating model has not yet demonstrated revenue conversion. Persistent losses leave results dependent on clinical execution and successful commercialization rather than an established recurring business.
Heavy And Deteriorating Cash Burn
Large recurring cash outflows increase the amount of capital Replimune must obtain to maintain trials and commercial activities. The deterioration in trailing free cash flow suggests that funding needs may remain substantial, making financial performance vulnerable if revenue ramps more slowly than planned.
Rising Leverage And Balance-sheet Pressure
The sharp increase in debt reliance reduces balance-sheet durability while the company continues to generate losses and negative cash flow. Higher leverage can constrain future financing choices and increase the financial burden that must be managed before the commercial portfolio produces sustained cash generation.
Replimune Group News
Replimune Group Lawsuit: Company Asks Court to Dismiss Securities Case Over RP1 FDA Approval Process
Replimune Group, Inc. (NASDAQ: REPL) and several current or former company leaders have asked a federal court in Massachusetts to dismiss an investor lawsuit accusing the company of securities-law violations tied
7R8 FAQ
What was Replimune Group’s price range in the past 12 months?
What is Replimune Group’s market cap?
When is Replimune Group’s upcoming earnings report date?
How were Replimune Group’s earnings last quarter?
Is Replimune Group overvalued?
Does Replimune Group pay dividends?
What is Replimune Group’s EPS estimate?
How many shares outstanding does Replimune Group have?
What happened to Replimune Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Replimune Group?
What is the TipRanks Smart Score and how is it calculated?
Replimune Group Stock Smart Score
Company Description
Replimune Group
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sushil Patel
- Employees
- 465
- Website
- www.replimune.com
- Address
- 500 Unicorn Park Drive, Woburn, MA, 01801, US
Replimune Group (7R8) Earnings & Revenues
7R8 Earnings Call
Earnings Call SentimentPositive
The call was strongly optimistic about TUDRIQEV's early commercial launch, with rapid account engagement, formulary additions, prescriptions, payer coverage, next-day delivery, and adoption across both academic and regional centers. The company also reported a stronger cash position and improved sequential net loss. Offsetting concerns were the absence of current-quarter product revenue, continued operating losses, higher SG&A tied to launch activities, lack of revenue guidance, and limited visibility into patient volumes and real-world treatment economics. Overall, the positive launch commentary and early adoption metrics significantly outweighed the stated challenges.
View all DE:7R8 earnings summaries7R8 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 1 | 5 |
| Technical Analysis | 4 | 1 | 5 |
| Moving Averages | 12 | 0 | 0 |
